



# Transfusion Reactions: Identifying and Providing Patient Care

*Widad Abdulwahab, RN, BScN, MN  
Transfusion Safety Nurse*

*Sunnybrook Health Sciences Centre*





# Learning Objectives

- ▶ Discuss the risks of blood product transfusions
- ▶ Discuss the signs and symptoms of a blood transfusion
- ▶ Review the common transfusion reactions and their causes
- ▶ Review clinical cases: discuss the management and the investigation results


# Transfusion Reaction Symptoms

## ► Fever, Chills/rigors, back pain



- Febrile non-hemolytic transfusion reaction (FNHTR)
- Bacterial Sepsis or contamination
- Acute hemolytic reaction

## ► Dyspnea, hypoxemia, tachypnea, ^HR, ^BP, Hypotension



- Transfusion related acute lung injury (TRALI)
- Transfusion-associated circulatory overload (TACO)
- Transfusion Associated Dyspnea (TAD)



## ► Urticaria, pruritus, flushing, bronchospasm, facial edema



- Minor allergic reaction
- Severe allergic reaction

## ► A hemolysis after Transfusion

- Acute hemolytic transfusion reaction
- Hemolysis not related to RBC alloantibodies
- Delayed hemolytic transfusion reaction



# Clinical Case I

- 58F with newly diagnosed AML
- On chemotherapy via Hickman line
- PMHX: HTN, hypothyroidism, and uterine fibroids. Daily fever
- Hb 74
- PLT 4
- WBC 0.3
- Received a pool of O Neg platelet on July 31, 2020 (exp. July 31, 2020 @MN)



- Transfusion started at 10:48
- Reaction noted at 11:31
  - Chills/ Rigors
  - T 39, P 108, RR 18, BP **80/49**

	BACTERIAL CONTAMINATION	SYMPTOMATIC SEPTIC REACTIONS	FATAL BACTERIAL SEPSIS
Buffy coat platelet pool	1 in 1,000	1 in 10,000	1 in 200,000
1 unit of RBC	1 in 50,000	1 in 250,000	1 in 500,000

# Clinical Interventions and Investigation

Received O-negative Platelet on July 31, 2020. Start time 10:48; End time 11:31

Pre-transfusion Vitals	T 37.9, P 85, RR 18, BP 107/63	
Post-Tx reaction Vitals	T 39, P 108, RR 18, BP <b>80/49</b>	
Clinical Symptoms	Chills and rigors	
Treatment	<ul style="list-style-type: none"><li>➤ Stop transfusion</li><li>➤ Repeat Vital signs</li><li>➤ Check patient's ID and Blood compatibility label</li><li>➤ Repeat G&amp;S</li><li>➤ Notify MD</li></ul>	<ul style="list-style-type: none"><li>➤ Saline bolus</li><li>➤ Antipyretics</li><li>➤ Antibiotic</li></ul>
Investigation	<ul style="list-style-type: none"><li>• Blood Culture (PIV, CVAD)</li><li>• Product sent to BB for culture</li><li>• No growth was detect both patient and product culture</li></ul>	<ul style="list-style-type: none"><li>• No serological incompatibilities identified</li><li>• CBS notified - investigation completed</li><li>• CBS classified as FNHTR</li></ul>

# Result of Investigation and Conclusion



Conclusion	Febrile Non-hemolytic Transfusion Reaction
Relationship	Possible
Severity	Grade 1 (non-severe)
Outcome	Minor or No Sequelae


# Febrile Non-Hemolytic Transfusion Reaction (FNHTR)

- ▶ 38<sup>0</sup> C and > 1<sup>0</sup>C from baseline
- ▶ Fever is not always present - chills/rigors alone
- ▶ Common - 1/300 RBC and 1/20 platelets
- ▶ **Cause**
  - ▶ cytokines from WBC, soluble proteins in plasma
  - ▶ alloimmunized patients more susceptible
- ▶ **Management**
  - ▶ Fever only and <39<sup>0</sup> – MD assessment, Acetaminophen, continue cautiously – max 4hours from issue (low risk fever)
  - ▶ With fever >39<sup>0</sup> or associated symptoms – *consider bacterial contamination or acute hemolytic reaction until proven otherwise (high risk fever)*
  - ▶ Demerol for rigors but do not restart transfusion
- ▶ **Prevention**
  - ▶ Premed with antipyretic if recurs

# Clinical Presentation Suspected Bacterial Sepsis

- ▶ Fever > 39° C (fever > 38° C with rigors + hypotension)
- ▶ Bacterial Sepsis or contamination
  - Fever, chills/rigors tachycardia, hypotension, N/V, dyspnea
  - Occurs most commonly with Platelet transfusion
  - Accounts for 10% of transfusion associated death

1 in 10,000	Symptomatic bacterial sepsis, per pool of platelets. Sepsis is when you get an infection in your bloodstream or tissue
1 in 40,000	Wrong ABO (blood) group, per unit of red blood cells
1 in 40,000	Anaphylaxis, which is an extreme sensitivity to a drug or substance that can result in death
1 in 200,000	Death from bacterial sepsis, per pool of platelets
1 in 250,000	Symptomatic bacterial sepsis, per unit of red blood cells
1 in 500,000	Death from bacterial sepsis, per unit of red blood cells







# Management and Prevention of Suspected Bacterial Sepsis

## Management

- STOP the Transfusion!
- Collect patient blood culture from a different IV site
- Return blood product back to blood bank for culture and gram stain
- Supportive therapy (broad spectrum antibiotics)
- Report to blood bank
- Report CBS (blood bank)

## Prevention

- Skin is disinfected at donation site
- First 40 mL of blood collected is diverted in a pouch
- CBS/HQ culture platelets
- Proper blood storage (RBC stored @ 1-6 degrees)



# Clinical Case II



- ▶ 62 year old male end-stage renal disease on peritoneal dialysis
- ▶ Admitted to SBK with hypertension and peripheral vascular ds
- ▶ PMHX: CAD, NSTEMI, HTN, PD since 2018
- ▶ S/p left femoral-popliteal bypass
- ▶ Receives EPO 4000 IU for anemia prevention
- ▶ Received RBC for Hb 76 g/L on October 19, 2020
- ▶ RBC transfusion was given over 2 hours
- ▶ 30 min post transfusion completion rapid response called due to respiratory failure

# Clinical Intervention and Investigation

Received O-positive RBC on October 19, 2020. Start time 17:11; End time 19:12


Pre-transfusion vitals	35.5, 87, 20 NP 2L O2 sat 93%, 116/69
Post-Tx reaction vitals	35.6, 103, 24 O2 sat to 78%, NRB to 95%, 102/62
Clinical Symptoms	Hypoxemia, SOB, dyspnea, ^WOB, Decrease in O2 sat.
Treatment	Diuretics, Vasopressors, Supplementary O2, Mechanical Ventilation, Transfer to ICU,
Investigation	ECG- ST depression Lateral and Inf. Leads CXR – Severe pulmonary edema. Small bilateral pleural effusions.
Recommendation	Avoid transfusion, transfuse over 4hrs, premedicate with Lasix or remove extra 500mL during PD exchange




## Result of Investigation and Conclusion

Conclusion	Transfusion Associated Circulatory Overload
Relationship	Probable
Severity	Grade 3 (Life-threatening)
Outcome	Major or Long term sequelae (Myocardial Infarction)

# Transfusion Associated Circulatory Overload (TACO)



TRANSFUSION TRANSMITTED INJURIES SURVEILLANCE SYSTEM (TTISS), ONTARIO  
MAJOR ADVERSE EVENTS REPORTED 2008-2014<sup>77</sup>



- Circulatory volume overload temporarily associated with transfusion (within 12h) results from:
  - ❑ Impaired cardiac function, renal and pulmonary disease, severe anemia, and patients age > 70
  - ❑ Rapid rate of transfusion
  - ❑ Most commonly reported causes of transfusion-related mortality

# Clinical Presentation of TACO

- Dyspnea, tachypnea
- Decreased O2 saturations
- Cough, cyanosis, orthopnea
- Hypertension and Tachycardia
- Increased central venous pressure
- Pulmonary edema
- Elevation in B type natriuretic peptide (NP) levels (BNP or NT-pro BNP)



# Management of TACO



- ▶ Stop transfusion
- ▶ Administer oxygen and diuretics as needed
- ▶ Radiographic chest imaging
- ▶ If restarting transfusion, restart at a reduced transfusion rate



# Prevention of TACO



- ▶ Assess the patient prior to transfusion
- ▶ Consider pre-transfusion diuretics
- ▶ Monitor vital signs closely ( $\uparrow$ HR,  $\uparrow$ BP)
- ▶ Avoid transfusion more than 1 unit at a time
- ▶ Transfuse over 4 period of time
- ▶ Component can also be divided into smaller aliquots



# Clinical Case III


- 28M group O-positive admitted to SBK (July, 2020) for febrile neutropenia in the setting of Burkitt's Lymphoma
- Recently diagnosed with lymphoma. c/o of lower abdominal pain and ?appendicitis
- Underwent appendectomy with lymph node dissection
- Transfusion history: minor allergic reaction on Aug 2, 2020
- Hx Allergy: shrimp
- A transfusion reaction was reported on September 13, 2020 following transfusion of 1 pool of O-negative platelets.

# Clinical Intervention and Investigation

**Platelet O Neg exp 2020-09-15. Start time: 11:55; end time: 13:10**

Pre-transfusion vitals	37.3, 92, 18 RA, 97/66
Post-Tx reaction vitals	37.7, 109, 18 RA, 106/72
Clinical symptoms	Urticaria, hives (chest), allergic associated edema (swollen lips and eyes), cough, and wheezing
Treatment	antihistamine administered, symptoms resolved within 2 hours
Investigation	Report to blood bank Report to CBS
Recommendation	The use of washed RBCs and premedicate with antihistamine prior to future platelet transfusions

## Clinical Investigation cont.



- CBS did the investigation and contacted one of the donor
- Possibility of passive transfer of shrimp allergens via the transfused unit
- Serum shrimp IgE test (Shrimp ImmunoCAP f24) on patient serum
- Shrimp IgE was negative (sample drawn Sep 25)
- Recipient allergy history
- order total IgE, tryptase, and allergen specific serum IgE (ImmunoCAP f24) testing

# Result of Investigation and Conclusion

Conclusion	Severe Allergic Reaction
Relationship	Definite
Severity	Grade 2 (severe)
Outcome	Minor or No Sequelae

# Allergic Reaction

- ❖ 1 in 100 risk of events Minor Allergic Event (MAR)
- ❖ 1 in 40,000 risk of events Serious Allergic Reaction (SAR)

## **Minor Allergic Reaction Symptoms:**

- ❑ Erythema, hives, flushing, swelling and pruritus. Can develop w/n seconds to several hours after receiving blood transfusion.
- ❑ **Cause:** *related to factors in the plasma portion of the blood component*

## **Severe Allergic Reaction Symptoms:**


- ❑ Anaphylactic shock (tachycardia, hypotension)
- ❑ Bronchospasm (Dyspnea, SOB, wheezing, angioedema)
- ❑ Intestinal symptoms
- ❑ **Cause:**
  - Transfusing an allergen to a sensitized patient.
  - Allergens in plasma or active allergy in donor, passive transfer of IgE (drugs or food)
  - IgA and haptoglobin deficiency

## Treatment of Allergic Reaction

- Stop transfusion temporarily & maintain IV access
- Administer antihistamine
- Administer corticosteroids
- Prevention of future allergic reaction by pre-medicating the patient with antihistamine
- Administering blood products that containing less plasma or administer washed cellular products



## Clinical Case IV



- ▶ 69-year-old O+ female hospitalized with metastatic cholangiocarcinoma
- ▶ PMHX: stroke, NSTEMI, kidney and spleen infarcts
- ▶ She developed severe HF with increased dyspnea
- ▶ She has a history of multiple pregnancies
- ▶ No history of transfusion
- ▶ Received RBC transfusion on Oct 6<sup>th</sup> and developed severe respiratory distress → RRT



# Clinical Intervention and Investigation



Received O positive RBC exp. Oct 27, 2020. Start time 01:55, end time 02:07

Pre-transfusion vitals	37.3, 128, 40, 108/60 NP 1L - O2 sat 94%	
Post-Tx reaction vitals	38.1, 145, 45, 71/31, NP 1L - O2 sat 85%	
Clinical Symptoms	^WOB, tachypnea, SOB, tachycardia, hypotension, hypoxemia, O2 saturation <90%, PO2 <60 mmHg)	
CXR	Mild congestion, mild bilateral infiltrate, prominent pulmonary vasculature	
Treatment	<ul style="list-style-type: none"> <li>• Stop transfusion</li> <li>• assessed by RRT</li> <li>• Supplemental Oxygen (.35 FM to 100% NRB)</li> <li>• Hydromorphone - improve dyspnea</li> </ul>	<ul style="list-style-type: none"> <li>• Lasix 40mg IV</li> <li>• Hemodynamic support (Levophed)</li> <li>• Fluid bolus for hypotension</li> </ul>
Investigation & Reaction workup	<ul style="list-style-type: none"> <li>• Hgb: 73, WBC 12.1</li> <li>• BNP 8,249 (6,337)</li> <li>• Patient Cx- neg (pre-tx)</li> </ul>	<ul style="list-style-type: none"> <li>• No evidence of blood group or serological incompatibility</li> <li>• Product Cx neg</li> <li>• Anti HPA-5b detected</li> <li>• Anti- Fya, anti-HLA</li> <li>• Positive anti-neutrophil antibodies</li> </ul>
CBS notified	TRALI form submitted	



# Result of Investigation and Conclusion



Conclusion	Transfusion Related Acute Lung Injury
Relationship	Probable
Severity	Grade 3 (Life-threatening)
Outcome	Death



# Transfusion Related Acute Lung Injury (TRALI)

- ▶ A rare but serious syndrome characterized by sudden acute respiratory distress following transfusion
- ▶ In patients with no evidence of acute lung injury prior to transfusion
- ▶ Symptoms:
  - Occur during or within 6 hours of transfusion
  - No other risk factors for ALI
- ▶ **Cause:** not fully understood, multiple factors, immune mediated
  - ▶ Donor WBC/HLA/HNA antibodies – *From female donor*
  - ▶ Patient WBC/HLA/HNA antibodies
  - ▶ Bioactive substances in blood reacting with certain 'at risk' patients

# Signs & Symptoms of TRALI

- Severe pulmonary edema
  - ❖ Chest X-Ray - 'white-out'
  - ❖ CVP normal
- Copious secretions from ETT
- Hypoxia, dyspnea, cyanosis, cough
- Tachycardia
- Sometimes hypertension initially
- Hypotension (mild to mod)
- Fever 1-2<sup>o</sup>
- Acute transient Leukopenia



# TRALI Management

- Supportive care
- 70–80% need ventilatory support
- 100% need oxygen
- Diuretics and steroids not believed to be useful
- 90% recover in 2-3 days
- No permanent lung damage
- TRALI mortality -1 in 5,000 plasma containing transfusions
- Proper reporting of possible TRALI to CBS/HQ

# TRALI Prevention Strategies



- Follow transfusion guidelines
- Use plasma from male donors
- Use puffy coat platelet pools suspended in male plasma
- Use plateletpheresis collected from male donors
- Deferral of donors confirmed to be implicated in TRALI episode

# References

- ▶ AABB Quick Reference Guide for NHSN hemovigilance Module: Adverse Reaction Definitions (2014). Retrieved from: <http://www.aabb.org/research/hemovigilance/Documents/AABB-Quick-Reference-Guide-NHSN-Hemovigilance-Module.pdf>
- ▶ Callum, J.L., Pinkerton, P.H., Lima, A., Lin, Y. (2016). *Bloody Easy. Blood Transfusions, Blood Alternatives and Transfusion Reactions. A Guide to Transfusion Medicine. 4<sup>th</sup> edition*
- ▶ Duran, J., Siddique, S., & Cleary, M. (2014). Effects of Leukoreduction and Premedication With Acetaminophen and Diphenhydramine in Minimizing Febrile Nonhemolytic Transfusion Reactions and Allergic Transfusion Reactions During and After Blood Product Administration: A Literature Review With .. *Journal of Pediatric Oncology Nursing, 31*(4), 223–229. <https://doi.org/10.1177/1043454214532029>
- ▶ Delaney, M., Wendel, S., Bercovitz, R. S., Cid, J., Cohn, C., Dunbar, N. M., Apolseth, T. O., Popovsky, M., Stanworth, S. J., Tinmouth, A., Van De Watering, L., Waters, J. H., Yazer, M., & Ziman, A. (2016). Transfusion reactions: prevention, diagnosis, and treatment. *Lancet, 388 North American Edition*(10061), 2825–2836. [https://doi.org/10.1016/S0140-6736\(15\)01313-6](https://doi.org/10.1016/S0140-6736(15)01313-6)
- ▶ International Society of Blood Transfusion, ISBT. (2017). TACO Criteria Validation: ISBT Working-Parties. Retrieved from: <http://www.isbtweb.org/working-parties/haemovigilance>
- ▶ Polat, A. Ç., Yiğit, Y., Akyol Önder, E. N., Yıldırım, A. T., Ertan, P., & Gülen, H. (2020). Transfusion-related Acute Lung Injury: A Case Report. *Journal of Pediatric Research, 7*(4), 365–367. <https://doi.org/10.4274/jpr.galenos.2019.74419>
- ▶ TTISS-ON (2014-2018). Transfusion Reaction Report. Retrieved from: <https://ttiss.mcmaster.ca/wp-content/uploads/2019/12/Final-OntarioTTISS-Report-5-Year-2014-2018-Dec-6-2019.pdf>